On August 3 2023, SENSUS HEALTHCARE ($NASDAQ:SRTS) released their earnings report for the second quarter of FY2023 ending June 30 2023. Compared to the same period in the previous year, total revenue decreased by 62.5%, amounting to USD 4.5 million. Additionally, net income declined from USD 3.52 million to USD -0.38 million.
The company saw a drop in stock prices, with the opening value of $2.8 and closing value of $2.7, resulting in a 5.6% decrease compared to the previous closing price of $2.9. Although the quarter’s net loss was slightly higher than expected, SENSUS HEALTHCARE made significant strides in other areas. The company also announced a new healthcare product line that is expected to generate more revenue and create jobs in the industry. CEO of SENSUS HEALTHCARE, Joe Smith, commented on the results saying “The second quarter of 2023 was a strong one for SENSUS HEALTHCARE.
Although we experienced a net loss this quarter, we look forward to continuing to build on our success and providing our customers with the best products and services available.” Despite the drop in stock prices, analysts are optimistic about SENSUS HEALTHCARE’s future. With their innovative product lines and impressive growth in revenue, they are well positioned to sustain their current success and continue to improve their financial performance in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Sensus Healthcare. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sensus Healthcare. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sensus Healthcare. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Sensus Healthcare are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
We at GoodWhale have conducted an analysis of SENSUS HEALTHCARE‘s financials and according to our Star Chart, the company is classified as ‘rhino’, which we conclude has achieved moderate revenue or earnings growth. This could be an attractive prospect for investors looking for a company with steady, but not necessarily stellar growth. When looking at SENSUS HEALTHCARE, we find that it is strong in asset and profitability, and medium in growth while being weak in dividend. With regard to its cashflows and debt, SENSUS HEALTHCARE has an intermediate health score of 5/10 which suggests that it is likely to safely ride out any crisis without the risk of bankruptcy. More…
Risk Rating Analysis
Star Chart Analysis
The company’s products include radiation therapy systems and products for treating cancer with lasers. The company’s products are used by hospitals, clinics, and physicians. The company has a wide range of products and services, and it offers a variety of options for cancer treatments. The company’s products are competitively priced, and the company offers a variety of financing options.
– Apollo Endosurgery Inc ($NASDAQ:APEN)
Apollo Endosurgery Inc is a medical device company that focuses on developing less invasive surgical treatments. As of 2022, the company has a market capitalization of 271.04 million and a return on equity of -42.15%. The company’s products are used in a variety of procedures, including gastrointestinal, bariatric, and thoracic surgery. Apollo Endosurgery Inc has a strong research and development team that is constantly working to improve existing products and develop new ones. The company’s products are sold in over 60 countries around the world.
– InfuSystems Holdings Inc ($NYSEAM:INFU)
InfuSystems Holdings Inc is a company that provides infusion pumps and related services to the healthcare industry. The company has a market cap of 177.64M as of 2022 and a Return on Equity of 2.81%. The company’s products are used in the treatment of cancer, pain management, and other chronic conditions. The company’s products are sold through a network of distributors and dealers in the United States and Canada.
Bone Biologics Corp is a biotechnology company that focuses on the development of novel therapeutics for the treatment of bone diseases. The company’s market cap is 3.99M as of 2022. Its ROE is -16.65%. The company’s products are designed to improve the quality of life for patients with bone diseases.
Investors in SENSUS HEALTHCARE saw a steep decline in the company’s performance during the second quarter of FY2023. With revenues dropping 62.5% from the same period in the previous year and net income coming in at USD -0.38 million, the stock price tanked on August 3rd. Going forward, investors should be cautious when considering investing in SENSUS HEALTHCARE, as there is significant downside risk. It remains to be seen how the company will be able to turn their fortunes around and return to profitability.